One trial is exploring the use of logic-gated CEA CAR-T cells inhibited by HLA-A*02, thus requiring the tumor to express CEA and have somatic loss of HLA-A*02 (NCT05736731). This evidence concerns the gene CEACAM5 and neoplasm.